Key result
The troponin T R92Q mutation alters tropomyosin positioning, increasing molecular and cellular force generation during calcium-based activation and driving early disease pathogenesis.
Why the study?
The multiscale functional complexity of familial hypertrophic cardiomyopathy makes it challenging to deconvolve the primary biophysical molecular defect driving pathogenesis from downstream cellular changes.
Does the R92Q mutation in troponin T drive early disease pathogenesis in HCM through molecularly driven changes in mechanical tension?
Does the R92Q mutation in troponin T drive early disease pathogenesis in HCM through molecularly driven changes in mechanical tension?
Answers are grounded in this paper and cite their sources.
The R92Q mutation in troponin T drives early HCM pathogenesis through altered tropomyosin positioning and increased mechanical tension, activating adaptive mechanobiological signaling pathways.
Familial hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death, is primarily caused by mutations in sarcomeric proteins. The pathogenesis of HCM is complex, with functional changes that span scales from molecules to tissues. This makes it challenging to deconvolve the biophysical molecular defect that drives the disease pathogenesis from downstream changes in cellular function. Here, we examined a HCM mutation in troponin T, R92Q. We demonstrate that the primary molecular insult driving the disease pathogenesis is mutation-induced alterations in tropomyosin positioning, which causes increased molecular and cellular force generation during calcium-based activation. We demonstrate computationally that these increases in force are direct consequences of the initial molecular insult. This altered cellular contractility causes downstream alterations in gene expression, calcium handling, and electrophysiology. Taken together, our results demonstrate that molecularly driven changes in mechanical tension drive the early disease pathogenesis, leading to activation of adaptive mechanobiological signaling pathways.
No takes yet. Share an insight, caveat, or question.
Clippinger et al. (2020) studied Familial hypertrophic cardiomyopathy (HCM). Troponin T R92Q mutation was evaluated on Mutation-induced alterations in tropomyosin positioning and cellular force generation. The troponin T R92Q mutation alters tropomyosin positioning, increasing molecular and cellular force generation during calcium-based activation and driving early disease pathogenesis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: